

Insulin-like Growth Factor Binding Protein-7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study

James L. Januzzi Jr, MD¹; Javed Butler, MD, MPH, MBA²; Naveed Sattar, PhD, FRCP, FRCPath³; Jialin Xu, PhD⁴; Wayne Shaw, DSL⁵; Norman Rosenthal, MD⁵; Michael Pfeifer, MD⁶; Kenneth W. Mahaffey, MD⁷; Bruce Neal, MB ChB, PhD⁸; Michael K. Hansen, PhD⁴

¹Cardiology Division, Massachusetts General Hospital and Baim Institute for Clinical Research, Boston, MA, USA; ²University of Mississippi, Jackson, MS, USA; ³Glasgow Cardiovascular Research, Glasgow, UK; ⁴Janssen Research & Development, LLC, Spring House, PA, USA; ⁵Janssen Research & Development, LLC, Raritan, NJ, USA; ⁶Janssen Scientific Affairs, LLC, Titusville, NJ, USA; ⁷Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; ⁸The George Institute for Global Health and Charles Perkins Centre, University of Sydney, Sydney, Australia and Imperial College London, London, UK.

Running title: IGFBP7 and diabetic kidney disease in CANVAS

Address for Correspondence:

James L. Januzzi Jr, MD
Massachusetts General Hospital

32 Fruit Street, Yawkey 5984, Boston, MA, 02114

P: +1-617-726-3443, F: +1-617-643-1620

E: jjanuzzi@partners.org

Word count: 3183

Table/figure count: 2 figures, 2 tables (4 supplemental tables, 2 supplemental figures)

Abstract

Objective: To analyze the association between concentrations of plasma insulin-like growth factor binding protein-7 (IGFBP7) with renal and cardiac outcomes among participants with type 2 diabetes and high cardiovascular risk.

Research Design and Methods: Associations between IGFBP7 levels and clinical outcomes were assessed among participants in the Canagliflozin Cardiovascular Assessment Study (CANVAS) with type 2 diabetes and high cardiovascular risk.

Results: Among CANVAS participants, 3577 and 2898 had IGFBP7 measured at baseline and 1 year, respectively. Per log-unit higher concentration, baseline IGFBP7 was significantly associated with the composite renal endpoint of sustained 40% reduction in eGFR, need for renal replacement therapy, or renal death (hazard ratio [HR]=3.51; $P<0.001$), and the composite renal endpoint plus cardiovascular death (HR=4.90; $P<0.001$); other outcomes including development or progression of albuminuria were also predicted by baseline IGFBP7. Most outcomes were improved by canagliflozin regardless of baseline IGFBP7; however, those with baseline concentrations ≥ 96.5 ng/mL appeared to benefit most from canagliflozin relative to first progression of albuminuria compared to those with lower baseline IGFBP7 (HR=0.64 vs 0.95; $P_{\text{interaction}}=0.003$). Canagliflozin did not lower IGFBP7 concentrations by 1 year; however, at 1 year, higher IGFBP7 concentrations more strongly predicted the composite renal endpoint (HR=15.7; $P<0.001$). Patients with rising IGFBP7 between baseline to 1 year had the highest number of composite renal events.

Conclusions: Plasma IGFBP7 concentrations predicted renal and cardiac events among participants with type 2 diabetes and high cardiovascular risk. More data are needed regarding circulating IGFBP7 and progression of diabetic kidney disease and its complications.

Study registration: ClinicalTrials.gov Identifier: NCT01032629

Introduction

Patients with type 2 diabetes have a heightened risk for development of glomerulosclerosis, tubulointerstitial fibrosis, proteinuria, and progressive reduction in estimated glomerular filtration rate (eGFR) (1). Diabetes is a leading cause of need for renal replacement therapy (RRT), and diabetic kidney disease is accompanied by substantial risk for cardiovascular events, such as death. An unmet need is an objective means by which to predict diabetic kidney disease onset or its progression.

In the recent Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, among a population of patients with type 2 diabetes and high cardiovascular risk who are at risk for development or progression of diabetic kidney disease, compared to placebo, treatment with the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin significantly reduced rates of progressive albuminuria (2, 3). Furthermore, canagliflozin treatment reduced the frequency of the composite endpoint of sustained 40% reduction of eGFR, need for RRT, or death from cardio-renal causes (4-6). Effects of canagliflozin to improve renal outcomes and the composite of renal outcomes plus cardiovascular death were recently affirmed in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial (3).

Given the importance of diabetic kidney disease and therapies shown to mitigate its severity and associated complications, tools to predict its onset and progression would be desirable. Circulating biomarkers represent an attractive option for this application, given potential for detecting signals of disease that might not otherwise be recognized; however, most biomarkers reported to date have underperformed for predicting onset or progression of diabetic kidney disease and specific biomarkers identifying benefit of therapies to reduce onset or progression of diabetic kidney disease remain elusive. Insulin-like growth factor binding protein-7

(IGFBP7) is a 29 kDa protein secreted by numerous tissues of the body. It is a member of the senescence-associated secretory phenotype with pluripotent *in vivo* roles, notably including induction of G1/S cell cycle arrest (7). Prior work has linked urinary concentrations of IGFBP7 (measured together with tissue inhibitor of metalloproteinase-2) for prediction of acute kidney injury (8). Whether IGFBP7 measurement provides information in diabetic kidney disease is not known and its measurement in plasma for such evaluation has not been explored. Accordingly, circulating concentrations of IGFBP7 were measured among participants in the CANVAS trial. We hypothesized IGFBP7 concentrations would predict risk for kidney endpoints in the trial, and evaluated for presence of interaction between biomarker and effects of canagliflozin.

Methods

Patients

The study design, participant characteristics, and main results from the CANVAS Program have been previously published (2-6, 9, 10). The CANVAS Program was an integrated analysis of 2 similarly designed and conducted trials, CANVAS and CANVAS-Renal (CANVAS-R). Data from this analysis are solely from the CANVAS trial (see Supplemental Materials for a list of sites and investigators). Participants were individuals with type 2 diabetes (glycated hemoglobin [HbA1c] level $\geq 7.0\%$ and $\leq 10.5\%$) and high risk for cardiovascular events. The patients were either ≥ 30 years of age with a history of symptomatic atherosclerotic cardiovascular disease or ≥ 50 years of age with ≥ 2 risk factors for cardiovascular disease. Participants were required to have an eGFR > 30 mL/min/1.73 m². CANVAS participants were randomized (1:1:1) to canagliflozin 100 or 300 mg or placebo. All major cardiovascular events, kidney outcomes, and deaths were adjudicated by endpoint adjudication committees.

Figure 1 is a study flow diagram outlining participants in the present study. Samples for biomarker measurement in this *post hoc* analysis were collected from patients enrolled in the CANVAS trial who consented for the collection of samples for exploratory biomarker research. Approval was obtained from institutional review boards and independent ethics committees for each participating center.

Plasma samples were collected at baseline and year 1 and stored at -80°C . IGFBP7 was measured using a preclinical research-use only assay on an automated platform blinded to the treatment arm and visit information (Roche Diagnostics, Penzberg, Germany). The detection method for IGFBP7 was a sandwich immunoassay developed on the Elecsys[®] platform for electrochemiluminescence detection (Roche Diagnostics, Penzberg, Germany). Mouse monoclonal antibodies were generated and screened for specific detection of IGFBP7. Precision within-run coefficient of variation for IGFBP7 was 2%, the limit of detection was 0.01 ng/mL.

Outcomes

For the purposes of this analysis, we evaluated predictive ability of IGFBP7 concentrations at baseline and 1 year for key renal outcomes of the CANVAS Program; the statistical analysis plan was assembled prior to IGFBP7 measurement and analyses were performed according to intention to treat. The primary outcome measure of interest was the renal composite endpoint from CANVAS, comprising a 40% reduction in eGFR sustained for ≥ 2 consecutive measures, the need for RRT (dialysis or transplantation), or death from renal causes (defined as death with a proximate renal cause). Additional outcomes included progression to macroalbuminuria (among those without macroalbuminuria at baseline) and a composite progression of albuminuria (defined as more than a 30% increase in albuminuria and a change from either normoalbuminuria to microalbuminuria or macroalbuminuria, or from

microalbuminuria to macroalbuminuria). Lastly, given that the primary endpoint of the CREDENCE trial was a comparable composite renal endpoint plus cardiovascular death (3), this endpoint was included in the present analysis.

Statistical Analysis

Several questions were examined in this *post hoc* analysis: effects of canagliflozin on IGFBP7 concentrations from baseline to 1 year, associations between baseline IGFBP7 and outcomes, associations between IGFBP7 at 1 year and outcomes, and association between IGFBP7 categorical change at 1 year and outcomes. In each outcome analysis, canagliflozin treatment effect as a function of IGFBP7 status was examined.

To address non-normality, IGFBP7 values were log-transformed prior to analysis. Clinical demographic data and cardiovascular and renal outcomes data, including off-treatment events, were merged with IGFBP7 results. Given the similar treatment effect from both canagliflozin treatment regimens (100 and 300 mg daily), data from patients receiving either of the 2 doses were combined in this analysis. To estimate the treatment effect on IGFBP7 concentrations at 1 year, a base linear model was constructed for log-transformed biomarker levels at 1 year by selecting important baseline covariates in patients randomized to placebo in the main study based on Bayesian information criterion. The candidate covariates at baseline included age, eGFR, BMI, systolic blood pressure, HbA1c, duration of diabetes, urine albumin:creatinine ratio (UACR), history of heart failure, and history of diuretic treatment. The treatment term (canagliflozin vs placebo) was then added to a base model to test the treatment effect on

IGFBP7 concentrations at 1 year. The geometric mean ratio and 95% CI were estimated for canagliflozin compared with placebo, and the nominal *P* value was also reported.

In order to estimate the association between the clinical outcome endpoints and IGFBP7 levels, a base model was also constructed for each endpoint from the same candidate covariates described above (plus treatment) using Cox proportional hazards model; proportion of hazards were checked and verified. IGFBP7 concentrations at baseline and 1 year were subsequently added to explore the association between outcome endpoints and IGFBP7 concentrations. The hazard ratio (HR) for a 2.72 [=exp(1)]-fold increase in IGFBP7, 95% CI, and nominal *P* value were also reported. Model C-index and change in C-index with addition of IGFBP7 results to the model were calculated.

To provide a clinical context to results from IGFBP7 between treatment arms, IGFBP7 concentrations dichotomized at median baseline value of 96.5 ng/mL or examined across quartiles and the interaction of these values with treatment were added into the base model described previously.

All statistics were performed using R version 3.6.1, with 2-sided *P* values <0.05 considered significant.

Results

Of the 4330 participants enrolled in the CANVAS trial, plasma samples were collected and analyzed for NT-proBNP in 3577 participants at baseline and 2898 participants at 1 year (**Figure 1**). The baseline characteristics for participants with biomarker samples were balanced between those assigned to canagliflozin and placebo and were generally consistent with the overall CANVAS trial population (**Table 1**). On average, the study participants with biomarker samples were 62.5 ± 7.8 years of age, were more likely

to be male and white, and had type 2 diabetes for an average of 13.5 ± 7.4 years. Overall, those in this analysis had a baseline eGFR of 77.5 ± 18.5 mL/min/1.73 m² and UACR of 9.5 ± 36.6 mg/g.

Effects of Canagliflozin on IGFBP7 Concentrations

Baseline geometric mean concentrations of IGFBP7 were similar between those allocated to receive canagliflozin (97.6 ng/mL) or placebo (96.7 ng/mL). During follow up, a slight increase in IGFBP7 concentrations were seen in both treatment arms; geometric mean concentrations were again similar between those receiving canagliflozin versus placebo (99.0 vs 98.9 ng/mL). In models adjusted for log-transformed baseline IGFBP7, age, HbA1c, eGFR, UACR, and treatment assignment, the treatment effect of canagliflozin versus placebo at 1 year was not significant ($\beta = -0.0044$ [$-0.0201, 0.0113$]; $P = 0.58$). Findings were similar in sensitivity analyses with more parsimonious models. **Supplemental Table 1** details baseline and 1-year IGFBP7 concentrations by UACR status at baseline. This demonstrates substantially higher concentrations of IGFBP7 in those with micro- and macroalbuminuria at baseline and 1 year compared to those with normoalbuminuria. Treatment effect of canagliflozin on IGFBP7 by 1 year remained nonsignificant in those with microalbuminuria (ratio of mean IGFBP7 change canagliflozin/placebo = 0.98; $P = 0.27$); in those with macroalbuminuria at baseline ($n = 162$), ratio of mean IGFBP7 change (canagliflozin/placebo) by 1 year did not achieve statistical significance (0.89; $P = 0.11$).

Baseline IGFBP7 Concentration and Outcomes

Table 2 details association between baseline log-transformed IGFBP7 concentrations and outcomes of interest for this analysis among the 3577 study participants with samples for analysis in the CANVAS study. In adjusted analyses, higher concentrations of the

biomarker were associated with risk for the composite renal endpoint (HR, 3.51; 95% CI, 1.66-7.42; $P < 0.001$), the composite renal endpoint plus CV death (HR, 4.90; 95% CI, 3.16-7.60; $P < 0.001$), plus the composite renal endpoint plus progression to macroalbuminuria (HR, 3.80; 95% CI, 1.54-4.07; $P < 0.001$). Higher baseline IGFBP7 also predicted individual endpoints such as progression to macroalbuminuria, 40% decline in eGFR and the composite of first progression of albuminuria. As well, addition of IGFBP7 to the best models for predicting each outcome generally increased the C-index for most outcomes, though these increases were small. **Supplemental Table 2** details the same analyses with baseline treatment forced into the model; this demonstrates attenuation of the HR magnitude, but nearly all remained significant. **Supplemental Table 3** lists outcomes relative to the dichotomized baseline IGFBP7 concentration of 96.5 ng/mL. Larger reductions in risk were consistently seen in those with higher IGFBP7 but most outcomes did not demonstrate an interaction baseline IGFBP7 and treatment effect. One possible exception was the fact those with higher IGFBP7 concentrations appeared to specifically benefit from canagliflozin treatment with respect to the endpoint of first progression of micro- or macroalbuminuria where possible interaction between baseline IGFBP7 and canagliflozin effects was observed. For example, those with a baseline IGFBP7 ≥ 96.5 ng/mL demonstrated greater impact of canagliflozin versus placebo on first progression of albuminuria (44.7% vs 35.7%; HR, 0.64) than in those with lower IGFBP7 concentrations who showed similar rates of subsequent first progression of albuminuria whether randomized to placebo or canagliflozin (30.9% vs 32.2%; HR, 0.95; $P_{\text{interaction}} = 0.003$). Examined across quartiles of IGFBP7, larger effects of canagliflozin vs placebo were confirmed above the median split (**Figure 2**; $P_{\text{interaction}} = 0.03$).

One-year IGFBP7 Concentration and Outcomes

For the 2898 study participants with a baseline and 1-year sample, we then examined predictive ability of log-transformed IGFBP7 to predict outcomes (**Table 2**). Associations between log-transformed IGFBP7 at 1 year and risk for endpoints were consistent with baseline predictive ability for some endpoints and even stronger than the baseline values for others. For example, higher IGFBP7 concentrations at 1 year predicted the composite renal endpoint substantially more strongly than the baseline value (HR = 15.7; 95% CI = 7.68-32.0; $P < 0.001$; plotted HRs across 1-year IGFBP7 concentrations are detailed in **Supplemental Figure 1**). Much of this reflected ability of higher IGFBP7 concentrations at 1 year to very strongly predict subsequent 40% reduction in eGFR (HR = 14.8; 95% CI = 7.2-30.6; $P < 0.001$). Addition of log-transformed IGFBP7 concentrations increased the C-index for best models to predict each outcome. **Supplemental Table 4** demonstrates outcomes relative to the dichotomized IGFBP7 concentrations at 1 year, once again demonstrating substantial predictive ability of 1-year IGFBP7 to prognosticate subsequent cardio-renal outcomes. No interaction term was detected between 1-year IGFBP7 concentrations and treatment allocation relative to subsequent events but the absolute reductions in outcomes associated with canagliflozin treatment were greater in those with higher IGFBP7 concentrations.

IGFBP7 Categorical Analysis From Baseline to 1 Year

Given importance of both baseline and 1-year IGFBP7 concentrations, we then examined rates of the composite renal endpoint relative to baseline-to-1 year change in IGFBP7, relative to the dichotomous cut-point of 96.5 ng/mL. We further divided patients relative to treatment with placebo versus canagliflozin. As shown in **Supplemental Figure 2**, rates of the renal composite endpoint were particularly highest in those with elevated IGFBP7 concentrations at baseline and 1 year, where the impact of canagliflozin

treatment was most obvious. Notably, those starting the trial with elevated values but with lower concentrations at 1 year had outcomes similar to those with low concentrations at both time points, while those with rising concentrations had worse outcomes than would have been predicted by the baseline sample alone.

Discussion

In this *post hoc* analysis of patients with available blood samples in CANVAS, baseline concentrations of IGFBP7 were strongly prognostic for a wide range of kidney endpoints notably predicting progression of chronic kidney disease, albuminuria, and composite endpoints, including major renal outcomes. In addition, IGFBP7 concentrations also independently predicted the renal composite endpoint plus cardiovascular death (the primary endpoint of the recent CREDENCE trial). An elevated baseline IGFBP7 also appeared to specifically identify those likely to benefit from canagliflozin relative to first progression of albuminuria; however, this observation should be approached with caution given the non-prespecified nature of the analysis. While baseline concentrations of the biomarker were prognostic, in some circumstances a second IGFBP7 measurement at 1 year added potentially even stronger predictive value, particularly for subsequent decline in eGFR. Lastly, those patients with elevated IGFBP7 at baseline or 1 year seemed to have the worst outcomes and possibly greatest absolute gains from being treated with canagliflozin compared to placebo. As far as we are aware, these data are the first to link circulating IGFBP7 concentrations to major kidney endpoints in patients with type 2 diabetes.

IGFBP7 is a member of a large family of insulin growth factor binding peptides with pluripotent effects *in vivo*. Among the identified roles of IGFBP7 is participation in the senescence associated secretory phenotype (7), wherein cell cycle arrest is induced in damaged tissue; this process is associated with tissue aging, cell death, and fibrosis. Recent work regarding IGFBP7 has mainly

focused on the biomarker in patients with heart failure (11-16), where concentrations of IGFBP7 are higher in those with more severe disease and are associated with structural abnormalities of the heart (15, 16). Though urinary IGFBP7 has been associated with acute kidney injury (8), no data exist regarding the role of urine or circulating IGFBP7 to predict chronic kidney outcomes in patients with type 2 diabetes. Our results are thus highly novel and considerably extend results for blood-based measurement of IGFBP7 for renal and cardio-renal outcomes.

Prior data are limited regarding the meaning of IGFBP7 concentration in type 2 diabetes, though an association between circulating IGFBP7 concentrations and insulin resistance has been reported (17). Notably, using proteomic screening, Watanabe and colleagues reported induction of IGFBP7 in an *in vitro* model of tubulointerstitial damage following exposure to transforming growth factor β 1 (a key mediator of diabetic kidney disease) (18). In immunohistochemical analyses, IGFBP7 was found to be localized in tubular cell cytoplasm and its knock-down was associated with less cellular death. Furthermore, in the report by Watanabe, elevated urinary IGFBP7 concentrations were found in clinical samples from type 2 diabetes patients with proteinuria. As tubular injury is a critical determinant of development and manifestation of diabetic kidney disease, it is tempting to speculate whether circulating IGFBP7 concentrations in CANVAS patients reflect risk for tubular fibrosis and proteinuria. More studies are planned; our data suggest circulating IGFBP7 concentrations are promising as an early marker of renal tubular cell fibrosis and predictor of progressive kidney dysfunction with proteinuria among patients with type 2 diabetes.

In the CANVAS Program, canagliflozin reduced rates of major cardiac and renal events compared to placebo (2, 3). In the present analysis, we found consistent relative benefit of canagliflozin regardless of IGFBP7 concentration, such that with most

endpoints, no interaction between the drug and biomarker was present; however, among those with elevated IGFBP7 concentrations, rates of each complication studied were substantially higher, so absolute reductions in risk associated with canagliflozin were greater in such patients. Notably, interaction between IGFBP7 and benefit from canagliflozin was found relative to first progression of albuminuria; this finding is curious given aforementioned links between IGFBP7 and tubulointerstitial fibrosis. Lastly, patients with elevated IGFBP7 at both baseline and 1 year had the highest rates of worsening eGFR, and in these patients, reduction of events in those taking canagliflozin was particularly noteworthy. Prospective studies would be needed to confirm any potential role of IGFBP7 measurement to identify those at risk for diabetic kidney disease most likely to benefit from treatment with SGLT2 inhibitors.

This study is limited in that it was a retrospective *post hoc* study performed only in patients from the CANVAS study with available samples. While consistent across numerous kidney endpoints, these results are therefore hypothesis-generating and need confirmation. This is particularly so for the results suggesting an interaction between baseline IGFBP7 concentrations and subsequent benefits from canagliflozin on progression of albuminuria; this finding may be the result of chance and requires validation. Further analyses of IGFBP7 concentrations in patients suffering from established diabetic kidney disease are planned and these results will be useful to prepare the analytic approach. Potential for incomplete adjustment for confounding variables is another limitation, particularly as certain variables such as eGFR and albuminuria have substantial variation across measurements. Lastly, multiple comparisons were made without adjustment for multiplicity, although for a *post hoc* exploratory analysis such as this the need for such correction is debated.

In conclusion, among patients randomized to treatment with canagliflozin or placebo in CANVAS, elevated or rising concentrations of the tissue senescence biomarker IGFBP7 were associated strongly with subsequent risk for a wide range of renal complications and composite of renal events and cardiovascular death. An elevated baseline IGFBP7 appeared to associate with specific benefit from canagliflozin treatment with regards to reduction of albuminuria progression. Development and progression of kidney disease is a pivotal moment in the course of type 2 diabetes, but a major obstacle to preventing or treating diabetic kidney disease is a lack of reliable tools for its prognostication. The results of this study extend basic science data regarding IGFBP7 in diabetic kidney disease, and suggest a potential clinical role for blood measurement of IGFBP7 to predict diabetic kidney disease complications and possibly for selecting its treatment. Further studies of IGFBP7 in patients with diabetic kidney disease are planned.

Acknowledgments

The CANVAS trial was sponsored by Janssen Research & Development, LLC. Canagliflozin has been developed by Janssen Research & Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation. Technical editorial assistance was provided by Alanna Kahhan, ELS, of MedErgy, and was funded by Janssen Research & Development, LLC.

Data Availability

Clinical data from the CANVAS Program are available in the public domain via the Yale University Open Data Access Project (<http://yoda.yale.edu/>).

Conflicts of Interest

J.L. Januzzi Jr is supported by the Hutter Family Professorship; is a Trustee of the American College of Cardiology; has received grant support from Novartis and Abbott; has received consulting income from Abbott, Janssen, Novartis, Pfizer, Merck, and Roche Diagnostics; and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, Bayer, CVRx, Janssen, and Takeda. J. Xu, W. Shaw, N. Rosenthal, M. Pfeifer, and M.K. Hansen are full-time employees of Janssen Pharmaceuticals, Inc. J. Butler reports relationships with Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceuticals, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sanofi, V-Wave Ltd, and Vifor. N. Sattar has consulted for Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Napp, Novo Nordisk, and Sanofi; and has received grant support from Boehringer Ingelheim. K.W. Mahaffey's financial disclosures can be viewed at <http://med.stanford.edu/profiles/kenneth-mahaffey>. B. Neal has received research support and has served as a consultant and speaker for Janssen, with all fees paid to his employer. He interacts regularly on a nonfinancial basis with multiple large corporations in the pharmaceutical industry, the food processing industry, and the quick service restaurant industry in Australia and overseas.

Author Contributions

J.L.J. and M.H. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. J.L.J. wrote the paper, had full access to the study design information, and had final responsibility for the decision to submit for publication. J.L.J., J.B., N.S., J.X., W.S., N.R., M.P., K.M., B.N., and M.H. contributed to the design and conduct of the study and interpretation of the data. All authors provided input into subsequent drafts and approved the final version for submission.

References

1. Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. *Nat Rev Dis Primers* 2015;1:15018
2. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. *Lancet Diabetes Endocrinol* 2018;6:691-704
3. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;380:2295-2306
4. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017;377:644-657
5. Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. *Circulation* 2018;138:1537-1550
6. Neuen BL, Ohkuma T, Neal B, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS Program. *J Am Soc Nephrol* 2019;30:2229-2242
7. Severino V, Alessio N, Farina A, et al. Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells. *Cell Death Dis* 2013;4:e911
8. Zhang D, Yuan Y, Guo L, Wang Q. Comparison of urinary TIMP-2 and IGFBP7 cut-offs to predict acute kidney injury in critically ill patients: a PRISMA-compliant systematic review and meta-analysis. *Medicine (Baltimore)* 2019;98:e16232
9. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial. *Am Heart J* 2013;166:217-223 e211
10. Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. *Diabetes Obes Metab* 2017;19:387-393
11. Gandhi PU, Chow SL, Rector TS, et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. *J Card Fail* 2017;23:20-28
12. Gandhi PU, Gaggin HK, Redfield MM, et al. Insulin-like growth factor-binding protein-7 as a biomarker of diastolic dysfunction and functional capacity in heart failure with preserved ejection fraction: results from the RELAX trial. *JACC Heart Fail* 2016;4:860-869
13. Gandhi PU, Gaggin HK, Sheftel AD, et al. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? *Am J Cardiol* 2014;114:1543-1549
14. Januzzi JL Jr, Packer M, Claggett B, et al. IGFBP7 (insulin-like growth factor-binding protein-7) and neprilysin inhibition in patients with heart failure. *Circ Heart Fail* 2018;11:e005133
15. Ibrahim NE, Afilalo M, Chen-Tournoux A, et al. Diagnostic and prognostic utilities of insulin-like growth factor binding protein-7 in patients with dyspnea. *JACC Heart Fail* 2020;8:415-422

16. Kalayci A, Peacock WF, Nagurney JT, et al. Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure. *ESC Heart Fail* 2020;
17. Liu Y, Wu M, Ling J, et al. Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population. *Sci Rep* 2015;5:10227
18. Watanabe J, Takiyama Y, Honjyo J, et al. Role of IGFBP7 in diabetic nephropathy: TGF-beta1 induces IGFBP7 via Smad2/4 in human renal proximal tubular epithelial cells. *PLoS One* 2016;11:e0150897

Table 1. Baseline Characteristics of CANVAS Study Participants With Samples Available for IGFBP7 Analysis

Characteristic*	Canagliflozin (n = 2384)	Placebo (n = 1193)
Age, years	62.8 (7.9)	62.5 (7.8)
Female, n (%)	789 (33)	395 (33)
Race, n (%)		
White	1941 (81)	968 (81)
Asian	233 (10)	121 (10)
Black	55 (2)	31 (3)
eGFR, mL/min/1.73 m ²	77.2 (18.7)	76.8 (19.0)
Body mass index, kg/m ²	32.7 (6.1)	32.6 (6.2)
SBP, mmHg	136.4 (15.9)	137.2 (15.8)
HbA1c, %	8.2 (0.9)	8.2 (0.9)
HbA1c, mmol/mol	66 (9.8)	66 (9.8)
Diabetes duration, y	13.6 (7.5)	13.4 (7.5)
Urine albumin:creatinine ratio, mg/g	9.1 (35.7)	11.3 (40.4)
History of HF, n (%)	296 (12)	170 (13)
Diuretic use, n (%)	1109 (47)	552 (46)
Sulphonylurea use, n (%)	1043 (44)	521 (44)
GLP-1 use, n (%)	60 (3)	26 (2)
Statin use, n (%)	1787 (75)	866 (73)
Insulin use, n (%)	1258 (53)	621 (52)

Metformin use, n (%)	1737 (73)	858 (72)
RAAS inhibitor use, n (%)	1950 (82)	977 (82)
Beta blocker use, n (%)	1210 (51)	605 (51)

IGFBP7, insulin-like growth factor binding protein-7; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; HF, heart failure; SD, standard deviation; GLP, glucagon-like peptide; RAAS, renin-angiotensin-aldosterone system.

*Data are mean (SD) unless otherwise indicated. **Table 2.** Log-transformed IGFBP7 at Baseline and 1 Year Relative to Subsequent Outcomes in the CANVAS Study

Baseline IGFBP7									
Events	HR _{adj} (95% CI)*	P	C-index with Clinical covariates only	C-index with baseline IGFBP7 only	C-index with both (improvement from clinical covariates only)	HR _{adj} (95% CI)*	P	C-index with Baseline and 1-year IGFBP7	C-index (improvement from clinical covariates and baseline IGFBP7)
Sustained decline in eGFR by 40% [†]	2.27 (1.05, 4.93)	0.038	0.73	0.69	0.73 (0)	14.8 (7.2, 30.6)	<0.001	0.77	0.79 (+0.04)
Progression to macroalbuminuria	2.50 (1.54, 4.07)	<0.001	0.81	0.63	0.81 (0)	3.80 (1.80, 7.80)	<0.001	0.66	0.81 (0.01)
First progression of albuminuria	1.80 (1.36, 2.38)	<0.001	0.56	0.56	0.58 (+0.01)	1.76 (1.16, 2.65)	0.007	0.56	0.57 (+0.01)
Cardiovascular death	6.55 (3.93, 10.9)	<0.001	0.66	0.67	0.69 (+0.03)	2.69 (0.86, 8.35)	0.09	0.65	0.68 (0)

Renal composite [‡]	3.51 (1.66, 7.42)	0.001	0.73	0.70	0.74 (+0.01)	15.7 (7.68, <0.001 32.0)	0.77	0.80 (+0.04)
Renal composite plus cardiovascular death	4.90 (3.16, 7.60)	<0.001	0.67	0.67	0.70 (+0.03)	6.90 (4.10, <0.001 11.7)	0.68	0.71 (+0.01)
Renal composite plus progression to macroalbuminuria	3.80 (2.50, 4.07)	<0.001	0.63	0.64	0.66 (+0.03)	7.40 (4.50, <0.001 12.2)	0.68	0.69 (+0.02)

IGFBP7, insulin-like growth factor binding protein-7; eGFR, estimated glomerular filtration rate; HR_{adj}, adjusted hazard ratio.

*Covariates for adjustment were selected using the Bayesian information criterion in patients randomized to placebo in the main study along with baseline IGFBP7 and treatment allocation. Improvement in the C-index was change above a base model of covariates excluding biomarker concentrations.

[†]40% decrease in eGFR was sustained for ≥ 2 consecutive measures.


[‡]The renal composite endpoint from CANVAS comprised a 40% decrease in eGFR (sustained for ≥ 2 consecutive measures), the need for renal replacement therapy (dialysis or transplantation), or renal death.

Figure Legends

Figure 1. Study flow for CANVAS IGFBP7 analysis. IGFBP7, insulin-like growth factor binding protein-7.


Figure 2. Reduction of first progression of micro- or macroalbuminuria as a function of treatment assignment (canagliflozin or placebo) across baseline IGFBP7 concentrations. Specific benefit from canagliflozin versus placebo appeared present in those patients with higher IGFBP7 values (interaction *P* value = 0.03). IGFBP7, insulin-like growth factor binding protein-7.

Figure 1. Study flow for CANVAS IGFBP7 analysis.



IGFBP7, insulin-like growth factor binding protein-7.

Figure 2. Reduction of first progression of micro- or macroalbuminuria as a function of treatment assignment (canagliflozin or placebo) across baseline IGFBP7 concentrations. Compared to the first quartile, specific benefit from canagliflozin versus placebo appeared present in those patients with higher IGFBP7 values (interaction *P* value = 0.03).



IGFBP7, insulin-like growth factor binding protein-7.

Supplemental Materials

Sites and investigators in the CANVAS trial

Argentina: Pablo Arias, Maria Rosa Ulla, Andres Alvarisqueta, Laura Maffei, Jose Osvaldo Fretes, Silvia Gorban De Lapertosa, Virginia Visco, Georgina Sposetti, Javier Farias, Eduardo Francisco Farias, Maria Cecilia Cantero, Rodolfo Feldman, Maria Carolina Ridruejo, Pedro Calella, Cesar Zaidman; **Australia:** Stephen Stranks, Peak Man Mah, Alison Nankervis, Duncan Topliss, Georgia Soldatos, Richard Simpson, Murray Gerstman, David Colquhoun, Ferdinandus De Looze, Robert Moses, Michael Suranyi, Samantha Hocking, David Packham, Duncan Cooke, Karam Kostner; **Belgium:** Eric Weber, Chris Vercammen, Luc Van Gaal, Jozef Tits, Bart Keymeulen, Chantal Mathieu; **Canada:** Naresh Aggarwal, Dan Dattani, Francois Blouin, Richard Dumas, Sam Henein, Patrick Ma, Ali Najarali, Michael Omahony, Tracy Pella, Wilson Rodger, Daniel Shu, Vincent Woo, Brian Zidel, Lew Pliamm, Brian Ramjattan, Ronald Akhras, Jasmin Belle-Isle, Stuart Ross, Geza Molnar; **Colombia:** Juan Manual Arteaga, Ivonne Jarava; **Czech Republic:** Alena Andresova, Miloslava Komrskova, Cyril Mucha, Tomas Brychta, Dagmar Bartaskova, Romana Urbanova, Tomas Spousta, Jana Havelkova, Tomas Sedlacek, Milan Kvapil; **Estonia:** Ülle Jakovlev, Verner Fogel, Liina Viitas, Mai Soots, Maire Lubi, Marju Past, Jelena Krasnopejeva; **Germany:** Hasan Alawi, Klaus Busch, Felix Klemens Pröpper, Andrea Thron, Stephan Jacob, Andreas Pfützner, Ludger Rose, Thomas Segiet, Christine Kosch, Andrea Moelle; **Great Britain:** Melanie Davies, Hamish Courtney, Martin Gibson, Luigi Gnudi, Frances Game, John Wilding, Thozhukat Sathyapalan, Miles Fisher, Shenaz Ramtooila, Satyan Rajbhandari, Maurice Okane; **Hungary:** Eleonora Beke, Ferenc Poor, Karoly Nagy, Gyozo Kocsis, Tamas Oroszlan, Peter Faludi, Mihaly Gurzo; **India:** Sathyanarayana Srikanta, Mala Dharmalingam, Bala Murugan, Pramod Gandhi, Bipin Sethi, Sosale Aravind, Sharda Ardhanareeshwaran, Arpan Bhattacharyya, Ganapathi Bantwal, Vijay Viswanathan, Paramesh Shamanna, Banshi Saboo, Viswanathan Mohan, Reshma Parmaj, Kirti Kumar Modi, Sindhu Joshi, Sunil Jain, Sanjay Kalra, Arun Chankramath Somasekharan, Prabha Adhikari, Ajay Kumar, Harshada Kudalkar, Rajiv Passey, Mathew John, Sadasivarao Yalamanchi, Keyur Parikh, K.P. Rajesh, Rajesh Nair, Ajay Kumar, Sasi Kumar, Lily Rodrigues, Pawan Gangwal, Pankaj Agarwal, Sandeep Kumar Gupta, Abhay Amrutlal Mutha, Shailaja Dilip Kale, Ravindra Laxman Kulkarni, Sandip Chudasama, Kamal Sharma, Anoop Nambiar, Aniruddha Tangaonkar, Vaishali Deshmukh, Biswakesh Majumdar, Rajendran Veerappan, Deepak Namjoshi; **Israel:** Itamar Raz, Julio Weinstein, Ilana Harman Boehm, Victor Vishlitzky; **Luxembourg:** Frederic Dadoun; **Malaysia:** Rajesh P. Shah, Lai Seong Hooi, Alexander Tan, Wan Mohamad Wan Bebakar, Mafauzy Mohamed, Amir S. Khir, Norlela Sukor, Khalid Abdul Kadir; **Mexico:** Enrique Morales, Sergio Zuñiga, Melchor Alpizar, Cesar Calvo, Rolando Zamarripa, Juan Rosas, Armando Vargas; **The Netherlands:** Max Nieuwdorp, Vicdan Kose, Susanne Kentgens, Gloria Rojas, Wouter Van Kempen, Jacqueline Hoogendijk, Mazin Alhakim, Victor Gerdes, Marcel Hovens, Johan Berends, A. Woittiez, Cees Jan Smit, B. Dekkers, Wilco Spiering, Marcel K. Van Dijk-Okla, Ben P.M. Imholz, Ruud J.M. Van Leendert, Marije Ten Wolde, Peter J.H. Smak Gregoor; **New Zealand:** Russell Scott, Jeremy Krebs, John Baker, Joe Singh, Calum Young; **Norway:** Gisle Langslet, Hans Olav Hoivik, Torbjorn Kjaernli, Sigbjorn Elle, Eric Gjertsen, Knut Risberg, Andreas Tandberg, Leidulv Solnoer, Per Anton Sirnes; **Poland:** Tadeusz Dereziński, Malgorzata Arciszewska, Edward Franek, Ewa Szyprowska, Dariusz Sowinski, Robert Petryka, Beata Czakanska-Dec, Grazyna Pulka, Katarzyna Jusiak, Mariusz Dabrowski, Piotr Kubalski, Malgorzata Wojciechowska, Andrzej Madej, Danuta Pupek-Musialik; **Russia:** Natalia Blinova, Ludmila Kondratjeva, Anatoly Kuzin, Mikhail Boyarkin, Tatyana Gomova, Alexander Khokhlov, Sergey Vorobjev, Olga Mirolyubova, Svetlana Boldueva, Olga Ershova, Marina Ballyzek, Olga Smolenskaya, Sergey S. Yakushin, Dmitry

Zateyshchikov, Mikhail Arkhipov, Alexandr Kuzmenko, Ivan Maksimov, Igor Motylev, Vladimir Rafalskiy, Leonid Strongin, Tatyana Treshkur, Natalya Volkova, Olga Barbarash, Tatiana Raskina, Leonid Bartosh, Inna Nikolskaya, Elena Shutemova, Viktor Gurevich, Natalia Burova, Elena Vorobyeva, Denis Andreev, Boris Bart, Tatiana Khlevchuk, Lyudmila Gapon, Ivan Gordeev, Nikolai Gratsiansky, Alsu Zalevskaya, Sergey Sayganov, Oleg Solovyev, Galina Reshedko, Natalia Shilkina, Petr Chizhov, Julia Shapovalova, Alexander Sherenkov, Olga Reshetko, Vladimir Simanenkoy; **Spain:** Juan Garcia Puig, Jose Saban, Jose Pascual, Jose Dominguez, Elias Delgado, Carlos Calvo, Manuel Vida, Santiago Duran, Francisco Tinahones, Jordi Salas, Jose Miguel Gonzalez, Manuel Monreal, Armand Grau, Andreu Nubiola, Pere Alvarez; **Sweden:** Kaj Stenlöf, Pekka Koskinen, Carl-Johan Lindholm, Ulrik Mathiesen, Katarina Berndtsson Blom, Bengt-Olov Tengmark, Hans Jul-Nielsen; **Ukraine:** Oleksandr Larin, Svetlana Panina, Svitlana Kovalenko, Olena Voloshyna, Vera Tseluyko, Olga Gyrina, Vadim Vizir, Olga Barna, Maryna Dolzhenko, Yuriy Mostovoy, Vadim Korpachev, Boris Mankovskiy, Mykola Vatutin; **United States:** Charles Arena, Basil Akpunonu, Rahfa Zerikly, Claire Baker, Toby Briskin, Darlene Bartilucci, Joshua Barzilay, Christian Breton, John Buse, Richard Cherlin, Michael Cobble, Clarence Ellis, Raymond Fink, Alan Forker, Ronald Garcia, Priscilla Hollander, Angela House, Daniel Hyman, Richard Ingebretsen, David Jack, Judith Kirstein, Kerri Kissell, Daniel Lorber, Donald McNeil, Wendell Miers, Alex Murray, Robert Call, Stephen T. Ong, Fernando Ovalle, Robert Pearlstein, Veronica Piziak, Daniel Pomposini, David Robertson, Julio Rosenstock, Ulrich Schubart, Shaukat Shah, Rodney Stout, Mark Turner, James Wallace, Leonard Chuck, Edmund Claxton, Emily Morawski, Alan Wynne, Carol Wysham, Michael Alderman, Walter Patton, Bryan Pogue, Arnold Silva, Roger Guthrie, Sam Lerman, Robert Madder, Wendy Miller, Daniel Weiss, Dean Kereiakes, Ronald J Graf, Negah Rassouli, James Greenwald, Hanna Abu-Nassar, Derek Muse, Vicki Kalen, Natalia Hegedosh, Richard Dobrusin, Glover Johnson, Tami Bruce, Gary Gleason.

Supplemental Table 1. Effects of Canagliflozin on IGFBP7 Concentrations Over Time as a Function of Albuminuria Status

	N	Geometric mean IGFBP7 at baseline	Geometric mean IGFBP7 at 1 Year	Mean fold change	Ratio of mean fold change (canagliflozin/placebo)	<i>P</i> *
All patients						
Placebo	930	95.1	99.0	1.04	0.98	0.11
Canagliflozin	1968	97.0	99.1	1.02		
Albumin/creatinine ratio <30 mg/g (normal)						
Placebo	676	92.9	95.9	1.03	0.99	0.53
Canagliflozin	1423	93.1	95.3	1.02		
Albumin/creatinine ratio 30-300 mg/g (microalbuminuria)						
Placebo	188	99.4	103.6	1.04	0.98	0.27
Canagliflozin	437	105.4	107.2	1.02		
Albumin/creatinine ratio >300 mg/g (macroalbuminuria)						
Placebo	63	106.0	121.5	1.15	0.89	0.11
Canagliflozin	99	121.6	124.0	1.02		

IGFBP7, insulin-like growth factor binding protein-7.

*Nominal *P* value on treatment effect on mean IGFBP7 fold-change from baseline.

Supplemental Table 2. Log-transformed IGFBP7 at Baseline and 1 Year Relative to Subsequent Outcomes in the CANVAS Study after adjusting for baseline medication.

Per log-unit increase of IGFBP7								
Baseline IGFBP7						1-year IGFBP7		
Events	HR _{adj} (95% CI)*	P	C-index with Clinical covariates only	C-index with baseline IGFBP7 only	C-index with both (improvement from clinical covariates only)	HR _{adj} (95% CI)*	P	C-index with Baseline and 1- year IGFBP7
Sustained decline in eGFR by 40% [†]	1.66 (0.79, 3.51)	0.18	0.72	0.69	0.73 (+0.01)	13.6 (6.5, 28.5)	<0.001	0.78
Progression to macroalbuminuria	2.09 (1.24, 3.53)	0.008	0.81	0.63	0.81 (0)	3.41 (1.60, 7.26)	0.002	0.67
First progression of albuminuria	1.66 (1.25, 2.21)	<0.001	0.58	0.56	0.59 (+0.01)	1.68 (1.11, 2.55)	0.015	0.58
Cardiovascular death	4.67 (2.71, 8.06)	<0.001	0.69	0.67	0.70 (+0.01)	2.20 (0.70, 6.85)	0.18	0.67
Renal composite [‡]	2.54 (1.15, 5.60)	0.021	0.72	0.70	0.74 (+0.02)	14.3 (6.90, 29.7)	<0.001	0.78
								0.80 (+0.05)
								0.81 (0)
								0.59 (0)
								0.70 (0)
								0.81 (+0.04)

Renal composite plus cardiovascular death	3.58 (2.24, 5.70)	<0.001	0.69	0.67	0.71 (+0.02)	5.87 (3.38, 10.2)	<0.001	0.69	0.72 (+0.01)
Renal composite plus progression to macroalbuminuria	3.23 (2.08, 5.02)	<0.001	0.65	0.64	0.67 (+0.02)	6.94 (4.15, 11.6)	<0.001	0.69	0.70 (+0.02)

IGFBP7, insulin-like growth factor binding protein-7; eGFR, estimated glomerular filtration rate; HR_{adj}, adjusted hazard ratio.

*Covariates for adjustment were selected using the Bayesian information criterion in patients randomized to placebo in the main study along with baseline IGFBP7 and treatment allocation. Baseline medications adjusted for include baseline use of diuretic, sulphonylurea, GLP-1 receptor agonists, statins, insulin, metformin, RAAS inhibitors, and beta blocker. Improvement in the C-index was change above a base model of covariates excluding biomarker concentrations.

†40% decrease in eGFR was sustained for ≥ 2 consecutive measures.

‡The renal composite endpoint from CANVAS comprised a 40% decrease in eGFR (sustained for ≥ 2 consecutive measures), the need for renal replacement therapy (dialysis or transplantation), or renal death.

Supplemental Table 3: Dichotomous Baseline IGFBP7 and Subsequent Outcomes in the CANVAS Study. The median concentration of 96.5 ng/mL was used.

Event	Baseline IGFBP7 ≥ 96.5 ng/mL		
	HR _{adj} (95% CI)	<i>P</i>	<i>P</i> _{interaction}
Sustained reduction of eGFR by 40%*	2.49 (1.41, 4.39)	0.002	0.39
Progression to macroalbuminuria	1.79 (1.25, 2.58)	0.002	0.24
First progression of albuminuria	1.70 (1.39, 2.07)	<0.001	0.002
Cardiovascular death	2.09 (1.33, 3.30)	0.002	0.58
Renal composite [†]	2.80 (1.60, 4.89)	<0.001	0.25
Renal composite plus cardiovascular death	2.30 (1.61, 3.30)	<0.001	0.17
Renal composite plus progression to macroalbuminuria	2.15 (1.58, 2.94)	<0.001	0.42

IGFBP7, insulin-like growth factor binding protein-7; eGFR, estimated glomerular filtration rate.

*40% decrease in eGFR was sustained for ≥ 2 consecutive measures.

[†]The renal composite endpoint from CANVAS comprised a 40% decrease in eGFR (sustained for ≥ 2 consecutive measures), the need for renal replacement therapy (dialysis or transplantation), or renal death.

Supplemental Table 4. Dichotomous 1-year IGFBP7 and Subsequent Outcomes in the CANVAS Study. Optimal Cut-off at Baseline for Predicting Risk was ≥ 110.3 ng/mL


Event	1-year IGFBP7 ≥ 110.3 ng/mL		
	HR _{adj} (95% CI)	<i>P</i>	<i>P</i> _{interaction}
Sustained reduction of eGFR by 40%*	2.86 (1.45, 5.62)	0.002	0.87
Progression to macroalbuminuria	2.19 (1.37, 3.52)	0.001	0.63
First progression of albuminuria	1.39 (1.08, 1.79)	0.01	0.29
Cardiovascular death	0.94 (0.51, 1.72)	0.84	0.91
Renal composite [†]	2.91 (1.48, 5.72)	0.002	0.60
Renal composite plus cardiovascular death	1.66 (1.04, 2.63)	0.03	0.60
Renal composite plus progression to macroalbuminuria	2.31 (1.54, 3.46)	<0.001	0.98

IGFBP7, insulin-like growth factor binding protein-7; eGFR, estimated glomerular filtration rate.

*40% decrease in eGFR was sustained for ≥ 2 consecutive measures.


[†]The renal composite endpoint from CANVAS comprised a 40% decrease in eGFR (sustained for ≥ 2 consecutive measures), the need for renal replacement therapy (dialysis or transplantation), or renal death.

Supplemental Figure 1. HR for renal composite endpoint of the CANVAS study as a function of the IGFBP7 concentrations at 1 year in the study.



HR, hazard ratio; IGFBP7, insulin-like growth factor binding protein-7.

Supplemental Figure 2. Rates of the renal composite endpoint by end of study as a function of baseline IGFBP7 and treatment allocation. Those study participants with IGFBP7 concentrations above 96.5 ng/mL at baseline and 1 year had the highest risk for the renal composite endpoint. Among these patients, treatment allocation to canagliflozin was associated with the largest reduction of this outcome measure.



IGFBP7, insulin-like growth factor binding protein-7.